Share
498 Posts.
lightbulb Created with Sketch. 613
clock Created with Sketch.
13/03/21
12:43
Share
Originally posted by Aqua65:
↑
Merchant Funds were in Polynovo from 5c . ( stated by Andrew Chapman , interview Andrew Judd two weeks ago- “Talk ya book” - March 2021 ) They had to sell PNV , all the way up . **They sold a lot at 50c !! And it has gone to $4. They sold at all levels also as Polynovo grew, to being over $2 billion market cap . Andrew is matter of fact about it - MOH just had to . But they’re solid investors and believe in the companies they’re invested in . They have a fund ceiling . I thought that they must have been selling . ( they flagged that they would sell first at $2 - and did - about 2 million shares? ) I really think that Merchant have been overall a great ally and friend of RAC . They’ve also acquired shares from some shareholders. ( esp overseas based - past Race Oncology consultants , and first CMO also I think . Made it easy for them to trade- in some of their shares - possibly Merchant approached them . ) They’re astute . Merchant have scooped up loose shares via options , and really helped tighten the share registry in terms acquiring unlisted options and converting , and some off market shares I would believe . They have attracted significant other investors and high wealth buyers - Eg . High wealth family office accounts . They do significant due diligence before ever they invest . And they identified and chose Race Oncology. Approached and offered cornerstone money as well as buying on market . Merchant like to identify opportunities early - **if the asset or end- goal company is going to be significant ; and has the experienced , management team with calibre; and if there is good company structure and a highly considered plan with best advice and respected industry leaders to assist to progress and de- risk the company . All has to be spot -on . Then , I think they even aim to backstop , and be a solid cornerstone investor to the company - but with a $100 million Opportunities Fund overall ceiling , they will sell down as higher levels reached. They have to . There isn’t enough liquidity for them otherwise and they’re beholden to their investors in the fund - to de- risk and grow the fund while also giving a return to investors . Returns typically have been ~ 25% , with focused management overall . Merchant helped to raise awareness about this company we are invested in . MOH have also been early change- makers imo , and supporters of brilliant Australian(ASX listed ) Biomed and Biotech companies. Thank god for them too . Significant early major money support has been been historically rare in cornerstone investing in the Biotech and Biomed areas - by Funds until now . I think we are in a new , and good era . Investors are far more educated. Specific Fund managers are more scientifically oriented also than in the past . 2021 - is very much the year for Biotech and worthy emerging Biomedical companies ! ARK investments notably have stated , and some of the wealthiest people and funds in the world are also seeing the true value and potentials in biomedical companies - Bill Gates , Berkshire Hathaway included .
Expand
This makes a lot more sense in hindsight. At first glance, this would attract suspicion (IMO rightfully so). But after careful consideration, it probably just is unfortunate timing. Glad to see MOF remain a key investor for the long run. FWIW, a lot of the early shareholders who bought RAC for a few cents are already heavily de-risked (they could still exit mostly unscathed if the share goes down due to unforeseen circumstances). To continue attracting new investors in the $4-5-6-etc. it is critical that those investors be confident about the fundamental value of RAC. This is where major shareholders (MOF and RAC management) play an important role in maintaining trust among the retail investors. "Investment is a collaborative game, divestment is a competitive game."